Business
Virax Biolabs Group Limited Announces Closing of $5 Million Private Placement
Virax Biolabs Group Limited ("Virax" or the "Company") (Nasdaq: VRAX), an innovative biotechnology company dedicated to the advancement of immunology research and diagnostics, announced today the closing of its previously announced private placement of its securities for total gross proceeds of $5 million, before deducting placement agent fees and other offering expenses.
About this update from Virax Biolabs Group Limited
[{"type":"list","items":[{"val":[{"type":"text","content":"Extends cash runway into first half of 2028, beyond planned completion of ViraxImmune™ US based regulatory study in post-acute sequelae of COVID-19 ("PASC", or long COVID) and submission to the FDA, completion of UK based regulatory study in post-acute infection syndrome (PAIS) and submission to MHRA along with expansion of our immune-profiling platform and partnerships.","length":388,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":388,"olType":false},{"type":"text","content":"LONDON, Dec. 4, 2025 /PRNewswire/ -- Virax Biolabs Group Limited ("Virax" or the "Company") (Nasdaq: VRAX), an innovative biotechnology company dedicated to the advancement of immunology research and diagnostics, announced today the closing of its previously announced private placement of its securities for total gross proceeds of $5 million, before deducting placement agent fees and other offering expenses.","length":431,"tagName":"p"},{"type":"image","alt":"Logo (PRNewsfoto/Virax BioLabs Group Limited)","displaySize":"","headline":null,"caption":"Logo (PRNewsfoto/Virax BioLabs Group Limited)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":60,"url":"https://media.zenfs.com/en/prnewswire.com/3557d954e9714d423e9a669da95b5821"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/6T1.7_Kq0fbJ4kq3ce4yTw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTEwNjtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/3557d954e9714d423e9a669da95b5821","width":400,"height":60}},"href":"https://mma.prnewswire.com/media/2730505/Virax_Biolabs_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"Virax sold and issued 12,500,000 of its ordinary shares (or ordinary share equivalents) and preferred investment options to purchase up to 12,500,000 ordinary shares for a combined purchase price of $0.3999 per pre-funded warrant and accompanying preferred investment option. The pre-funded warrants have an exercise price of $0.0001 per share, may be exercised commencing on the issuance date and do not expire. The preferred investment options have an exercise price of $0.40 per ordinary share and are exercisable immediately upon issuance for a period of five years from the effective date of the Initial Registration Statement (as defined below).","leng...